Lonza, a Switzerland-based company recognized as the world’s largest contract drug manufacturer, announced Wednesday that it is raising its full-year core profit margin target to a range of 33% to 34%.
The company credited strong operational performance and contributions from maturing growth projects as the driving forces behind the improved outlook.
Previously, Lonza had projected that its core earnings before interest, taxes, depreciation, and amortization margin would grow to above 32% of sales for the year.
